Verruca Vulgaris
12
1
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
8.3%
1 terminated out of 12 trials
88.9%
+2.4% vs benchmark
17%
2 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (12)
Cold Atmospheric Plasma Device Extension Study
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Cantharidin and Occlusion in Verruca Epithelium
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
Photodynamic Therapy in Treatment of Verrucae
Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
ALC-919 For The Treatment Of Common Warts
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts